Amgen Stock Soars on Raised Guidance and Late-Stage Pipeline Hopes

Amgen's stock has surged 57% in the last twelve months, and its recent revenue guidance raise has only added to its momentum.

The company's management points to six key growth drivers, a group of products that collectively grew at a 26% year-over-year clip and now account for nearly 70% of product sales.

However, the real excitement and risk lies in Amgen's late-stage pipeline, particularly with experimental obesity drug MariTide, which has the potential to be a game-changer with its monthly therapy design.

The market is pricing in an unusual amount of turbulence, with implied volatility sitting at 30%, but this also means that there could be sharp swings ahead.